FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 161 filers reported holding FATE THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 0.34 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $467,000 | -24.3% | 20,820 | +100.0% | 0.05% | -37.8% |
| Q3 2021 | $617,000 | +14.9% | 10,410 | +68.2% | 0.07% | +37.0% |
| Q2 2021 | $537,000 | -17.9% | 6,190 | -21.9% | 0.05% | -27.0% |
| Q1 2021 | $654,000 | +116.6% | 7,927 | -9.9% | 0.07% | +64.4% |
| Q2 2020 | $302,000 | -42.9% | 8,798 | -67.4% | 0.04% | -47.1% |
| Q4 2019 | $529,000 | +192.3% | 27,025 | +161.9% | 0.08% | +183.3% |
| Q1 2019 | $181,000 | +82.8% | 10,317 | -52.4% | 0.03% | +30.4% |
| Q1 2017 | $99,000 | – | 21,654 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $34,095 | 9.92% |
| Redmile Group, LLC | 12,957,222 | $130,738,370 | 5.35% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $10,465,913 | 2.67% |
| Casdin Capital, LLC | 2,050,000 | $20,684,500 | 1.60% |
| DAFNA Capital Management LLC | 550,940 | $5,558,985 | 1.57% |
| Artal Group S.A. | 2,600,000 | $26,234 | 1.46% |
| Monaco Asset Management SAM | 250,000 | $2,522,500 | 0.76% |
| Parametrica Management Ltd | 32,254 | $325,443 | 0.67% |
| Boxer Capital, LLC | 1,250,000 | $12,612,500 | 0.66% |
| Bellevue Group AG | 4,861,279 | $49,050,305 | 0.65% |